Tagrisso + chemo showed favourable trend in OS in EGFR-mutated advanced lung cancer with further follow-up in FLAURA2 Ph 3 trial March 26, 2024
FAILED TRIAL: Ph 3 KEYLYNK-006 trial of KEYTRUDA + maintenance LYNPARZA did not meet dual primary endpoints of OS and PFS in 1L EGFR/ALK/ROS1 WT patients with metastatic nonsquamous NSCLC March 26, 2024
Positive Topline Results Announced from Ph 1 Portion of Ph 1/2a Trial of IMM-1-104 in RAS-Mutant Solid Tumors March 26, 2024
Positive Findings announced from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research March 26, 2024
Additional Positive Data announced from Ph 1 Part of BEXMAB Study in Both Higher-Risk HMA-Failed MDS and R/R AML March 26, 2024
CheckMate -9DW Trial of Opdivo + Yervoy Meets Primary Endpoint of OS for the 1L Treatment of Advanced HCC March 26, 2024
Lynparza and Imfinzi demonstrated strong clinical benefit and more than doubled median duration of response vs. chemo in patients with MMR-proficient advanced or recurrent endometrial cancer March 26, 2024
KEYTRUDA + CRT Significantly Improved OS Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer March 18, 2024
Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma March 18, 2024
New clinical data from 2L ONSEMBLE trial provides further evidence of the efficacy of onvansertib + FOLFIRI/bev in bev naïve RAS-mutated mCRC patients March 12, 2024
Positive results announced from DREAMM-8 Ph 3 trial for Blenrep versus SoC combo in R/R multiple myeloma March 12, 2024
Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Ph 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4 announced March 12, 2024
FAILED TRIAL: Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma Announced March 12, 2024
Data from Ph 1 Trial of MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma published March 12, 2024
Vudalimab monotherapy generally well tolerated with encouraging clinical benefit for heavily-pretreated patients with high-risk metastatic CRPC March 5, 2024
Encouraging Safety & Efficacy Data in Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in metastatic CRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors Announced March 5, 2024
Tagrisso demonstrated efficacy benefit for patients with unresectable, Stage III EGFR-mutated lung cancer in LAURA Ph 3 trial February 26, 2024
KEYTRUDA Reduced the Risk of Death by 38% Versus Placebo as Adjuvant Therapy for Patients With RCC at an Increased Risk of Recurrence Following Nephrectomy February 26, 2024
KEYTRUDA Significantly Improved DFS as Adjuvant Therapy Versus Observation in High-Risk Patients With Localized MIBC After Surgery February 26, 2024
DREAMM-7 Ph 3 trial shows Blenrep combination nearly tripled mPFS vs SOC combination in patients with R/R multiple myeloma February 26, 2024
